These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 18846865)

  • 1. [TLV meets criticism: costs of antihypertensive agents can and should be reduced].
    Edling A; Löfmark R; Vinge E; Carlsson P; André M; Melltorp G; Edhag O; Dahlqvist R; Andersson I; Magnusson D
    Lakartidningen; 2008 Sep 17-23; 105(38):2592-3. PubMed ID: 18846865
    [No Abstract]   [Full Text] [Related]  

  • 2. [Non-biased (?) blood pressure experts criticize LFN].
    Hernborg A
    Lakartidningen; 2008 Sep 17-23; 105(38):2593-4. PubMed ID: 18846866
    [No Abstract]   [Full Text] [Related]  

  • 3. Hypertension control: improved, but not enough!
    Alderman MH
    Am J Hypertens; 2007 Apr; 20(4):347. PubMed ID: 17386338
    [No Abstract]   [Full Text] [Related]  

  • 4. [Discontinuation of subsidizing of certain antihypertensive agents is not well thought-out].
    Berggren B; Lindström T; Nyström F; Cizinsky S; Weiss L; Willenheimer R
    Lakartidningen; 2008 Aug 27-Sep 2; 105(35):2345-6. PubMed ID: 18831442
    [No Abstract]   [Full Text] [Related]  

  • 5. Out-of-pocket costs to users: medicine options for hypertension.
    Arredondo A
    Am J Hypertens; 2008 May; 21(5):492. PubMed ID: 18437138
    [No Abstract]   [Full Text] [Related]  

  • 6. Australia-United States Free Trade Agreement and the Australian Pharmaceutical Benefits Scheme.
    Sainsbury P
    Yale J Health Policy Law Ethics; 2004; 4(2):387-99. PubMed ID: 15536920
    [No Abstract]   [Full Text] [Related]  

  • 7. [Decisions by the state, county council's money and my patient. Consequences of the LFN survey of antihypertensive agents].
    André M; Andersén-Karlsson E; Landahl S; Löfmark R; Silfverhielm B; Skoglund I
    Lakartidningen; 2008 May 21-27; 105(21):1549-50. PubMed ID: 18574990
    [No Abstract]   [Full Text] [Related]  

  • 8. Barrier to trade or barrier to profit? Why Australia's Pharmaceutical Benefits Scheme worries U.S. drug companies.
    Hamilton C; Lokuge B; Denniss R
    Yale J Health Policy Law Ethics; 2004; 4(2):373-85. PubMed ID: 15536919
    [No Abstract]   [Full Text] [Related]  

  • 9. [Pfizer: TLV decision about antilipemic agents is founded on wrong basis].
    Brun J; Ohlsson-Onerud A; Sörensen N
    Lakartidningen; 2009 Apr 22-28; 106(17):1193-4; discussion 1194. PubMed ID: 19530431
    [No Abstract]   [Full Text] [Related]  

  • 10. Captive markets.
    Mettner J
    Minn Med; 2008 Nov; 91(11):12-3. PubMed ID: 19108536
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmaceutical Benefits Scheme (PBS).
    Louis WJ; O'Callaghan CJ; Krum H; Mander AG; Louis ES
    Med J Aust; 1994 Mar; 160(5):306-7. PubMed ID: 8107635
    [No Abstract]   [Full Text] [Related]  

  • 12. [They promise one thing and promise to keep something else].
    Jacobsen IA
    Ugeskr Laeger; 2004 Aug; 166(32):2694-5. PubMed ID: 15347184
    [No Abstract]   [Full Text] [Related]  

  • 13. [They promise one thing and promise to keep something else 2].
    Narvestad JB
    Ugeskr Laeger; 2004 Aug; 166(33):2819. PubMed ID: 15344867
    [No Abstract]   [Full Text] [Related]  

  • 14. [Hypertension trials--for whom?].
    Hjelmqvist B
    Lakartidningen; 2005 Nov 21-27; 102(47):3587; discussion 3588-9. PubMed ID: 16408397
    [No Abstract]   [Full Text] [Related]  

  • 15. [No value for money with certain antihypertensive agents].
    Edling A; Löfmark R; Vinge E; Carlsson P; André M; Melltorp G; Edhag O; Dahlqvist R; Andersson I; Magnusson D
    Lakartidningen; 2008 Nov 26-Dec 9; 105(48-49):3565. PubMed ID: 19133587
    [No Abstract]   [Full Text] [Related]  

  • 16. [A reply on subsidizing of antihypertensive agents: the problem is exceptional undertreatment of hypertension].
    Willenheimer R; Nyström F; Berggren B; Lindström T; Cizinsky S; Weiss L
    Lakartidningen; 2008 Oct 22-28; 105(43):3055-6. PubMed ID: 19024623
    [No Abstract]   [Full Text] [Related]  

  • 17. As drug payment model changes, confusion grows among insurers.
    Sipkoff M
    Manag Care; 2007 Feb; 16(2):56-9. PubMed ID: 17361511
    [No Abstract]   [Full Text] [Related]  

  • 18. [Innovation or pseudo-innovation: that is the question].
    Unger T
    Med Klin (Munich); 2006 Mar; 101(3):257-62. PubMed ID: 16648986
    [No Abstract]   [Full Text] [Related]  

  • 19. Senate GOP tosses drug bill. Law would have let Medicare negotiate costs directly.
    DoBias M
    Mod Healthc; 2007 Apr; 37(17):12. PubMed ID: 17479495
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharma APMs: Can the Industry Learn To Play Well With Others?
    Alston M; Pyenson B
    Manag Care; 2018 Sep; 27(9):31-32. PubMed ID: 30216160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.